Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT06608927
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
610 participants
INTERVENTIONAL
2024-12-13
2030-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A (Experimental Arm)
Quemliclustat, nab-paclitaxel and gemcitabine will be administered by IV infusion
Quemliclustat
Administered as specified in the treatment arm
Nab-paclitaxel
Administered as specified in the treatment arm
Gemcitabine
Administered as specified in the treatment arm
Arm B (Comparator Arm)
Placebo, nab-paclitaxel and gemcitabine will be administered by IV infusion
Placebo
Administered as specified in the treatment arm
Nab-paclitaxel
Administered as specified in the treatment arm
Gemcitabine
Administered as specified in the treatment arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quemliclustat
Administered as specified in the treatment arm
Placebo
Administered as specified in the treatment arm
Nab-paclitaxel
Administered as specified in the treatment arm
Gemcitabine
Administered as specified in the treatment arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have not been previously treated for PDAC in the metastatic setting.
1. Prior neoadjuvant and/or adjuvant therapy for PDAC is permitted if completed at least 12 months before randomization.
2. Prior palliative radiotherapy is allowed if completed at least 2 weeks prior to randomization and AEs have resolved to Grade 1 or less before randomization.
3. Prior and/or placement of a biliary stent/tube is permitted if any treatment-related AEs have improved to Grade ≤ 1 and the patient is not exhibiting any signs/symptoms of biliary obstruction.
* Eastern Cooperative Oncology Group PS of 0 to 1.
* At least 1 target lesion measurable by computed tomography (CT)/magnetic resonance imaging (MRI) per RECIST v1.1. not within a field of prior radiation therapy.
Exclusion Criteria
* History of brain metastases or leptomeningeal metastases.
* Prior treatment with a CD73 antagonist or inhibitor.
* Underlying medical conditions that, in the investigator or sponsor's opinion, will make the administration of study-specified therapy hazardous
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taiho Pharmaceutical Co., Ltd.
INDUSTRY
Arcus Biosciences, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Arcus Biosciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Arizona - Phoenix Campus
Phoenix, Arizona, United States
University of Arizona Cancer Center
Tucson, Arizona, United States
University of California San Diego Health
La Jolla, California, United States
Cancer & Blood Specialty Clinic - Los Alamitos
Los Alamitos, California, United States
Keck Medicine of USC - Keck Hospital of USC
Los Angeles, California, United States
Sutter Medical Center
Roseville, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
UCLA Health - Santa Monica Cancer Care
Santa Monica, California, United States
USOR - Rocky Mountain Cancer Centers - Denver - Midtown
Denver, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Miami Cancer Institute
Miami, Florida, United States
Piedmont Cancer Institute
Atlanta, Georgia, United States
Emory University Hospital
Atlanta, Georgia, United States
USOR - Illinois Cancer Specialists - Arlington Heights
Arlington Heights, Illinois, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Cancer Center of Kansas - Medical Arts Tower
Wichita, Kansas, United States
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, United States
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion
Grand Rapids, Michigan, United States
HealthPartners Cancer Research Center - Cancer Center at Regions Hospital
Minneapolis, Minnesota, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
MediSync Clinical Research - Hattiesburg Clinic
Hattiesburg, Mississippi, United States
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
New York University Medical Oncology Associates
New York, New York, United States
Columbia University Irving Medical Center - Herbert Irving Pavilion
New York, New York, United States
Memorial Sloan-Kettering Cancer Center - New York - Rockefeller Outpatient Pavilion
New York, New York, United States
Mount Sinai Medical Center Comprehensive Cancer Center
New York, New York, United States
James P. Wilmot Cancer Center
Rochester, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
USOR - Texas Oncology - Austin Midtown
Austin, Texas, United States
USOR - Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
USOR - Texas Oncology - San Antonio Medical Center
San Antonio, Texas, United States
USOR - Texas Oncology - Deke Slayton Cancer Center
Webster, Texas, United States
Inova Medical Group - Hematology Oncology - Arlington
Fairfax, Virginia, United States
Virginia Mason Medical Center
Seattle, Washington, United States
Summit Cancer Centers - Spokane Valley
Spokane, Washington, United States
USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center
Vancouver, Washington, United States
University of Wisconsin - Madison
Madison, Wisconsin, United States
Chris O'Brien Lifehouse
Camperdown, , Australia
Monash Health
Clayton, , Australia
Oncology West - Murdoch
Murdoch, , Australia
Wollongong Hospital
Wollongong, , Australia
Salzburg Cancer Research Institute
Salzburg, , Austria
Universitätsklinikum Sankt Pölten
Sankt Pölten, , Austria
Krankenhaus Der Barmherzigen Brüder Wien
Vienna, , Austria
Medizinische Universität Wien
Vienna, , Austria
Institut Jules Bordet
Anderlecht, , Belgium
Imeldaziekenhuis
Bonheiden, , Belgium
Algemeen Ziekenhuis Groeninge - Campus Kennedylaan
Kortrijk, , Belgium
Ottawa Hospital - General Campus
Ottawa, , Canada
Hôtel-Dieu de Sherbrooke
Sherbrooke, , Canada
Princess Margaret Cancer Centre
Toronto, , Canada
Sunnybrook Health Sciences Centre - Bayview Campus
Toronto, , Canada
Fakultni Nemocnice Brno
Brno, , Czechia
Nemocnice AGEL Nový Jičín a.s.
Nový Jičín, , Czechia
Fakultni nemocnice v Motole
Prague, , Czechia
Centre Georges François Leclerc
Dijon, , France
Hôpital Huriez
Lille, , France
Centre Léon Bérard
Lyon, , France
Centre Hospitalier Universitaire de Poitiers
Poitiers, , France
Gustave Roussy
Villejuif, , France
Katholisches Klinikum Bochum - St. Josef-Hospital
Bochum, , Germany
Krankenhaus Nordwest
Frankfurt am Main, , Germany
Facharztzentrum Eppendorf
Hamburg, , Germany
Katholisches Marienkrankenhaus
Hamburg, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
SLK-Kliniken Heilbronn - Klinikum am Gesundbrunnen
Heilbronn, , Germany
Otto-von-Guericke Universität
Magdeburg, , Germany
Elblandklinikum Riesa
Riesa, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
Universitätsklinikum Würzburg
Würzburg, , Germany
Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant Orsola-Malpighi
Bologna, , Italy
Ospedale di Cremona
Cremona, , Italy
Azienda Ospedaliero - Universitaria Careggi
Florence, , Italy
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, , Italy
Istituto Europeo di Oncologia
Milan, , Italy
Azienda Ospedaliero - Universitaria di Modena
Modena, , Italy
Istituto Oncologico Veneto - IRCCS
Padua, , Italy
Ospedale Guglielmo da Saliceto
Piacenza, , Italy
IRCCS Istituto Nazionale Tumori Regina Elena
Roma, , Italy
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas
Rozzano, , Italy
Azienda Ospedaliero Universitaria Delle Marche
Torrette, , Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, , Italy
National Cancer Center Hospital East
Kashiwa-shi, , Japan
Cancer Institute Hospital of JFCR
Kōtō City, , Japan
Osaka Prefectural Hospital Organization - Osaka International Cancer Institute
Osaka, , Japan
National Cancer Center Hospital
Tokyo, , Japan
Toyama University Hospital
Toyama, , Japan
Yamaguchi University Hospital
Ube, , Japan
Kanagawa Cancer Center
Yokohama, , Japan
Chonnam National University Hwasun Hospital
Hwasun, , South Korea
Cha Bundang Medical Center
Seongnam, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital
Seoul, , South Korea
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital Universitari Vall d'Hebrón
Barcelona, , Spain
Hospital General Universitario de Elche
Elche, , Spain
Institut Català d'Oncologia Girona (ICO Girona)
Girona, , Spain
Clínica Universidad de Navarra - Madrid
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario HM Sanchinarro
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Clinica Universidad de Navarra - Pamplona
Pamplona, , Spain
Hospital Universitario de Navarra
Pamplona, , Spain
Hospital Alvaro Cunqueiro - Clinico Universitario Vigo
Vigo, , Spain
Hospital Universitario Miguel Servet
Zaragoza, , Spain
University Hospitals Birmingham NHS Foundation Trust
Birmingham, , United Kingdom
Hull University Teaching Hospitals NHS Trust
Cottingham, , United Kingdom
Royal Free London NHS Foundation Trust
London, , United Kingdom
Sarah Cannon Research Institute London
London, , United Kingdom
University College London Hospitals NHS Foundation Trust
London, , United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
PRISM-1 - Public website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-513317-12-00
Identifier Type: CTIS
Identifier Source: secondary_id
jRCT2061240084
Identifier Type: OTHER
Identifier Source: secondary_id
PRISM-1
Identifier Type: -
Identifier Source: org_study_id